Promotion of HPV vaccination: potential gaps between knowledge and practices of Pakistani female family practitioners
Like most countries, cervical cancer is one of the foremost cancer types in Pakistani women. [1] [2] [3] Though human papillomavirus (HPV), the chief aetiological agent of cervical cancer, has a low prevalence in Pakistani women compared to its pervasiveness observed in females worldwide, its subtypes 16 and 18 are associated with about three-quarters of invasive cervical cancer cases in Pakistani women.
2 Thus awareness about the HPV vaccination that has recently been marketed in Pakistan is critical to the promotion of cancer prevention initiatives at the national level. Regrettably though, only one previous Pakistani study has explored the awareness about HPV vaccination in health personnel in a tertiary care setting, which was reported as low (approximately 9.3%). 4 As regards HPV vaccination, female family practitioners (FFPs) may have an edge over other health care personnel for vaccine promotion because of their proximity, both physically and culturally, with the at-risk population. 2 3 We were therefore interested in assessing the knowledge, attitudes and practices of FFPs in downtown Karachi, centre of the most populous metropolitan of the country. Of the 100 FFPs, who were conveniently sampled, the response rate was 99%. Two in fi ve (42.4%) FFPs were married, 37.4% had children and 31.3% were aged <26 years. Around half (47.5%) the FFPs had <3 years of practising experience, and the majority (60.6%) had no cancer care experience. Table 1 presents the percentages of correct responses to knowledge, attitude and practice regarding HPV vaccination. Briefl y, most (90.9%) FFPs identifi ed HPV as a frequent aetiological agent for cervical cancer but only one in fi ve knew about its prevalence (19.2%) and market availability (23.2%). Two in fi ve FFPs reported that the ideal age for vaccination was between 25 and 30 years. Although most FFPs (84.8%) agreed that HPV vaccine marketing is a good idea, only one-third (37.4%) were willing to prescribe it. Only 8.1% FFPs reported ever administering HPV vaccine, while others reported that they would administer it if the government promoted its use.
Overall, our brief survey did indicate some potential gaps between knowledge and practices regarding HPV vaccination in FFPs in Karachi. While most FFPs seemed to support the HPV vaccination, the majority of them were not fully aware of practicalities such as target age and vaccine availability. Other potential barriers observed were the perceptions regarding the offi cial standpoint on the HPV vaccination, as well as a lack of clarity regarding the government support that FFPs, or the population they serve, might have. We believe that for any future cancer prevention initiative to be successful the above knowledge gaps should be responded to by assessing the health promotion needs of the FFPs close to the atrisk population, in addition to conducting HPV cost-effectiveness studies to support wider consensus on vaccination. 
